NSPR

InspireMD, Inc. (NASDAQ:NSPR) is an Israeli medical device company founded in 2005 and headquartered in Tel Aviv-Yafo, Israel. The company specializes in developing and commercializing proprietary MicroNet stent platform technology for treating vascular and coronary diseases. InspireMD has been publicly traded since 2011 and operates primarily in international markets including Europe, Latin America, the Middle East, and Asia Pacific through local distributors. The company is currently preparing for its most significant milestone - entering the U.S. market with FDA approval expected for its flagship CGuard Prime system in 2025.